RASAL2 activates RAC1 to promote triple-negative breast cancer progression

Min Feng, Yi Bao, Zhimei Li, Juntao Li, Min Gong, Stella Lam, Jinhua Wang, Diego M. Marzese, Nicholas Donovan, Ern Yu Tan, Dave S.B. Hoon, and Qiang Yu

Cancer Therapeutics and Stratified Oncology and Computational Biology, Genome Institute of Singapore, Agency for Science, Technology, and Research (A*STAR), Biopolis, Singapore. Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California, USA. Department of General Surgery, Tan Tock Seng Hospital, Singapore. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Cancer and Stem Cell Biology, DUKE-NUS Graduate Medical School of Singapore, Singapore.

Patients with triple-negative breast cancer (TNBC) have a high incidence of early relapse and metastasis; however, the molecular basis for recurrence in these individuals remains poorly understood. Here, we demonstrate that RASAL2, which encodes a RAS-GTPase-activating protein (RAS-GAP), is a functional target of anti-invasive microRNA-203 and is overexpressed in a subset of triple-negative or estrogen receptor-negative (ER-negative) breast tumors. As opposed to luminal B ER-positive breast cancers, in which RASAL2 has been shown to act as a RAS-GAP tumor suppressor, we found that RASAL2 is oncogenic in TNBC and drives mesenchymal invasion and metastasis. Moreover, high RASAL2 expression was predictive of poor disease outcomes in patients with TNBC. RASAL2 acted independently of its RAS-GAP catalytic activity in TNBC; however, RASAL2 promoted small GTPase RAC1 signaling, which promotes mesenchymal invasion, through binding and antagonizing the RAC1-GAP protein ARHGAP24. Together, these results indicate that activation of a RASAL2/ARHGAP24/RAC1 module contributes to TNBC tumorigenesis and identify a context-dependent role of RASAL2 in breast cancer.

Introduction

Triple-negative breast cancer (TNBC), characterized by tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2), represents the most aggressive subtype of breast cancer, with a high rate of relapse and no available therapeutic targets (1, 2). Currently, chemotherapy is the main treatment modality for TNBC, but one-third of patients develop recurrence within 3 years of adjuvant therapy (3). One important goal of research is to identify novel prognostic biomarkers that can reliably stratify patients with TNBC according to clinical outcomes. This, however, has been hampered by a lack of understanding of the mechanisms underlying distant metastasis and early relapse in TNBC.

Among the many proposed mechanisms underlying metastasis (4, 5), microRNA-regulated (miRNA-regulated) transcriptional dynamics has emerged as a critical step (6). In human cancers, many miRNAs act as potential tumor suppressors and their downregulation leads to overexpression of cancer-promoting genes (7–9). Several miRNAs known to target and suppress invasion and metastasis are often found to be downregulated in breast cancers, consistent with a role in breast cancer progression (8, 10–14). These anti-invasive miRNAs suppress breast cancer cell invasiveness through various mechanisms. For example, members of the miR-200 family seem to inhibit the expression of genes associated with epithelial-to-mesenchymal transition (EMT) (15–17), a step considered critical for metastatic dissemination (18), while miR-126 and miR-126* modulate the tumor stromal microenvironment to inhibit cellular invasion (14, 19). Other miRNAs like miR-708 can attenuate metastasis by targeting the endoplasmatic reticulum and intracellular calcium levels (20). Here, we describe miRNA-203 as a key anti-invasive miRNA downregulated in TNBC and identify RASAL2 as a clinically relevant downstream target, with a critical role in promoting invasion and metastasis in TNBC.

Results

RASAL2 is a target of anti-invasive miR-203 and is overexpressed in TNBC or ER-negative tumors. As it has been found that anti-invasive miRNAs are often downregulated in TNBC, we therefore profiled the global miRNA expression in 2 highly invasive TNBC cell lines (MDA-MB-231 and BT-549) in comparison with that in 2 noninvasive luminal-type breast cancer cell lines (MCF-7 and BT474). Fifty-four miRNAs were found to be significantly downregulated in both TNBC cell lines as compared with the 2 luminal lines (using 3-fold cutoff, P < 0.01; Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI76711DS1). The top 10 miRNAs are shown in the expression heat map shown in Figure 1A. Among them are the 5 members of miR-200 family (miR-200a/b/c, miR-141, and miR-429), which is known to be anti-invasive by targeting and inhibiting EMT-promoting transcription factors such as ZEB1/2 (16, 17). We also found that miR-203 was among the most downregulated in TNBC cells. Although recent studies have indicated a tumor-suppressive role for miR-203 in several cancers types, including breast cancer (21–23), its functional targets in regulating breast cancer invasion have yet to be identified. In this study, we have chosen to focus on miR-203, with the objective to elucidate its targets that may have functions in TNBC tumorigenesis.
Figure 1. miRNA and mRNA profiling identifies concurrent deregulations of miR-203 and RASAL2 in TNBC. (A) Heat map of miRNA profiling showing the 10 top-ranked downregulated miRNAs in indicated cell lines. (B) Venn diagram of putative miR-203 target genes predicted by TargetScan and miRDB algorithms and the 103 TNBC upregulated genes identified previously (24) in addition to the 4 genes that overlap, with number of putative miR-203 target sites. (C) The diagram shows the 2 regions containing miR-203–binding sites (a single miRNA recognition element [MRE] in P1 and 6 MREs [MRE2–MRE7] in P2) of the luciferase reporter construct of the 3’ UTR of RASAL2. Reporter activity was normalized to wild-type reporter activity in cells expressing a nontargeting control (NC) microRNA. (D) qPCR and Western blot analysis of RASAL2 levels in MDA-MB-231 and BT-549 cells treated with miR-203 mimics. (E) qPCR and Western blot analysis of RASAL2 levels in MCF-7 and T47D cells treated with miR-203 antagomir inhibitor. (F) qPCR analysis of miR-203 and RASAL2 in breast tumor specimens. ΔCq, quantification cycle. (G) Representative images and quantification of IHC staining for RASAL2 in luminal or TNBC tumors. (H) Correlation analysis of RASAL2 and miR-203 in luminal and TNBC tumors expressing high (upper quartile) and low (lower quartile) levels of miR-203. (I) IHC analysis of the TMA cohort, showing the percentages of staining of different tumor subtypes (strong [67%–100%), moderate [34%–66%), or absent/weak [0%–33%]) for RASAL2 protein. (J) Scatter plot showing RASAL2 protein expression in indicated breast tumors. The data shown represent mean ± SEM of 3 independent experiments. Scale bar: 100 μm (G); 300 μm (I). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
To search for putative targets of miR-203, we used TargetScan (http://www.targetscan.org) and miRDB (http://mirdb.org) computational tools and identified a common set of 355 candidate genes whose 3’ untransluted regions (3’ UTRs) contain at least one putative miR-203–binding sequence (Figure 1B). A comparison of these candidate genes with a list of 103 genes that were previously identified as being overexpressed in both TNBC cell lines and clinical samples (24) revealed 4 putative miR-203 targets that are upregulated in TNBC (Figure 1B). Of these, RASAL2, which encodes the RAS protein activator like 2, a putative RAS-GTPase–activating protein (RAS-GAP), emerged as a top candidate whose 3’ UTR contains 7 putative miR-203–binding sites (Figure 1B), including 3 that are highly conserved (Supplemental Figure 1A).

To validate RASAL2 as a direct target of miR-203, we performed the 3’ UTR luciferase reporter assay using 2 pMIR-REPORT constructs: one containing the first miR-203–binding site (P1) and the other containing the remaining 6 sites that are closely clustered together in an 1,173-bp region (P2) (Figure 1C). The results showed that the ectopic miR-203 was able to repress the luciferase activity of both P1 and P2 constructs but not that of the constructs in which the respective miR-203–binding sites were mutated, supporting a direct interaction of miR-203 with RASAL2 3’ UTR (Figure 1C). Furthermore, ectopic expression of miR-203 in the TNBC MDA-MB-231 and BT-549 cells markedly reduced RASAL2 expression at both mRNA and protein levels (Figure 1D). Conversely, a synthetic antagonist inhibitor of miR-203 increased RASAL2 expression in luminal MCF-7 and T47D cells but not TNBC MDA-MB-231 and BT-549 cells (Figure 1E and Supplemental Figure 1B). Together, these results support RASAL2 as a direct target of miR-203.

Using quantitative PCR (qPCR) and Western blotting in a panel of breast cancer cell lines, we confirmed the downregulation of miR-203 and the upregulation of RASAL2 in TNBC lines as compared with that in non-TNBC lines (Supplemental Figure 1C). Importantly, in clinical tissue specimens we confirmed the significant downregulation of miR-203 and upregulation of RASAL2 in TNBC tumors compared with that in non-TNBC tumors (Figure 1F).

Expanded analyses using public databases, including GOBO (25), Oncomine (26), and The Cancer Genome Atlas (TCGA), have further confirmed RASAL2 upregulation in basal or TNBC cell lines and clinical samples, both in a panel of 55 breast cancer lines (Supplemental Figure 2, A and B) and in multiple clinical data sets (Supplemental Figure 2C). Of significant note, the TCGA analysis revealed a step-wise upregulation of RASAL2 toward aggressiveness, showing the highest expression in basal tumors, followed by HER2’ tumors and luminal tumors (Supplemental Figure 2D), in which RASAL2 was found to be strongly upregulated in approximately 31% of basal tumors (which often overlapped with TNBC tumors) compared with <6% in luminal tumors (Supplemental Figure 2E). TCGA analysis also revealed a potential RASAL2 gene amplification in a small set of basal tumors (4.9%) (Supplemental Figure 2E, top), indicating a possible alternative mechanism for RASAL2 upregulation.

Finally, RASAL2 protein level expression in clinical tissue specimens was evaluated by immunohistochemistry (IHC) analysis with a RASAL2 antibody whose specificity has been experimentally validated (Supplemental Figure 3). Consistent with the mRNA analysis, RASAL2 protein was found to be expressed at significantly higher levels in TNBC tumors compared with that in non-TNBC tumors (Figure 1G). Moreover, in patient samples expressing high and low levels of miR-203 we identified a significant inverse correlation between miR-203 and RASAL2 in TNBC tumors but not luminal tumors (Figure 1H).

The IHC result was further validated and expanded using a breast tissue microarray (TMA) that contained 74 breast cancer specimens of different subtypes. By using a cutoff to score strong, moderate, or weak levels of staining, we showed that RASAL2 was expressed strongly in 38% of TNBC tumors and 16% of HER2’ tumors but had little or no expression in luminal tumors (Figure 1I). Of note, the IHC staining was also able to show the striking difference in RASAL2 expression just based on the ER status (Figure 1J).

RASAL2 expression is positively associated with poor clinical outcomes, early metastasis, and disease recurrence in basal or ER-negative patients. To assess the clinical role of RASAL2 deregulation in breast cancer, we performed Kaplan-Meier meta-analyses using the GOBO online database (http://co.bmc.lu.se/gobo/), which consists of 10 breast cancer cohorts and 1,789 patients. In both overall survival and early distant metastasis and relapse-free survival analysis (within 5 years), we found that RASAL2 expression level was not prognostic in unselected patients (all patients), but an expression level in the top 30% was significantly associated with the poor outcomes in patients with basal tumors (which overlap largely with TNBC tumors though are not completely equivalent) and showed an opposite trend in patients with luminal tumors, as stratified based on the PAM50 gene signature (Figure 2, A and B, and ref. 27).

We next asked whether breast cancer stratification by just ER status is sufficient to demonstrate the prognostic value of RASAL2. The results showed that RASAL2 high expression was consistently associated with poor overall or metastasis- and relapse-free survivals in ER-negative patients, while they again showed an opposite trend in patients with ER-positive tumors (Figure 2C). Moreover, in the multivariate analysis, RASAL2 emerged as a stand-alone predictor of prognosis in ER-negative tumors (for tumors with low RASAL2 expression, hazard ratio = 0.47; P = 0.03), independent of other clinical parameters (Figure 2D). Thus, the role of RASAL2 in breast cancer seems to be context dependent: it is oncogenic in basal/TNBC or ER-negative tumors but can function as a tumor suppressor in luminal tumors. Indeed, the latter is consistent with a recent report showing a tumor-suppressive role of RASAL2 in luminal B breast cancers (28).

To further assess the role of RASAL2 in breast cancer metastasis progression, we analyzed RASAL2 expression using a breast cancer TMA containing tissue cores from 36 paired, localized primary tumors and matched lymph node metastasis specimens. IHC staining of ER expression in these tumor specimens showed 11 of 36 patients as ER positive and 25 of 36 as ER negative (using 5% ER positivity as a cutoff point). We found that 18 of 25 ER-negative tumors (72%) showed marked upregulation of RASAL2 in node metastasis compared with that in primary tumors (Figure 1G). Moreover, in patient samples expressing high and low levels of miR-203 we identified a significant inverse correlation between miR-203 and RASAL2 in TNBC tumors but not luminal tumors (Figure 1H).
mary tumors (Figure 2F), revealing a role of RASAL2 in TNBC tumor recurrence. Moreover, by analyzing the gene expression data associated with breast cancer chemoresistance and recurrence in the I-SPY 1 TRIAL (29), we observed that patients with

We next analyzed a set of TNBC primary tumors and matched recurrent tumors following the chemotherapy. qPCR analysis showed higher levels of RASAL2 expression in most of the recurrent tumors compared with that in the matched primary tumors (Figure 2F), revealing a role of RASAL2 in TNBC tumor recurrence. Moreover, by analyzing the gene expression data associated with breast cancer chemoresistance and recurrence in the I-SPY 1 TRIAL (29), we observed that patients with
RASAL2 has a similar oncogenic role in high-grade ovarian cancer. Intriguingly, by Oncomine analysis, we found that RASAL2 was markedly upregulated in high-grade serous ovarian cancer in both mRNA levels and gene copy numbers (Supplemental Figure 4, A and B). This was further confirmed by IHC analysis using a commercial ovarian cancer TMA (Supplemental Figure 4C). Moreover, RASAL2 expression showed a progressive upregulation toward metastasis in Fédération Internationale de Gynécologie Obstétrique staging analysis of the Meyniel ovarian data set (Supplemental Figure 4D and F).

recurrent tumors had higher levels of RASAL2 in their primary tumors; importantly, this upregulation of RASAL2 upon recurrence was only seen in ER-negative tumors ($P = 0.035$) and not in ER-positive tumors ($P = 0.77$) (Figure 2G). Collectively, these clinical data further support the oncogenic role of RASAL2 in TNBC or ER-negative tumors.

It has been shown recently through large-scale genomic analysis that TNBC and high-grade serous ovarian cancers showed a remarkable similarity in the molecular portraits (30). We next asked whether RASAL2 has a similar oncogenic role in high-grade ovarian cancer.
Finally, high RASAL2 expression was consistently associated with poorer disease outcomes in multiple cohorts of ovarian cancer (Supplemental Figure 4E). These data support a role of RASAL2 in high-grade serous ovarian cancer. Taken together, these findings suggest a role of RASAL2 as an oncogene in TNBC and ER-negative breast tumors as well as in aggressive ovarian tumors.

RASAL2 promotes TNBC tumorigenesis independently of its GAP activity. We next sought to test our hypothesis by experimentally determining the functional role of RASAL2 in TNBC tumorigenesis. MDA-MB231-LN is a metastasis subline of MDA-MB-231 cells (Supplemental Figure 5, A and B). Consistent with the clinical samples, MDA-MB231-LN cells were found to express more abundant RASAL2 compared with the parental cells (Supplemental Figure 5C) and thus were chosen for the subsequent functional studies (hereafter referred to as MB231-LN). In an in vitro Matrigel invasion assay, RASAL2 knockdown by 2 independent siRNAs markedly reduced the invasiveness of MB231-LN and BT-549 cells (Supplemental Figure 5D) but not the cell proliferation in monolayer culture (Figure 3A). The specificity of RASAL2 knockdown on cell invasion was further confirmed by a rescue experiment using ectopic expression of RASAL2 and a third siRNA targeting the 3′ UTR of RASAL2 (Fig-
RASAL2 knockdown also markedly reduced the migration of MB231-LN cells, as measured by a wound healing assay (Figure 3B) and 3D Matrigel growth (Figure 3D). In addition, RASAL2 knockdown also reduced the cell properties associated with breast cancer cell stemness, including mammosphere-forming ability in a serum-free suspension cell culture (Figure 3E) and the CD44 hi CD24 lo cell population (Figure 3F). Together, these results indicate that RASAL2 is required to support the aggressive growth of TNBC cells, including invasion, migration, and self-renewal, though it was not necessarily required for the cell proliferation. In luminal tumors, RASAL2 has been shown to act as a tumor-suppressive RAS-GAP protein, and its downregulation leads to the activation of RAS/MAPK signaling (28). Given the observed pro-oncogenic role of RASAL2 in TNBC and that depletion of RASAL2 was able to inhibit the invasion capacity in both RAS wild-type (BT-549) and RAS mutant (MDA-MB-231) TNBC cells, we hypothesized that RASAL2 oncogenic activity in TNBC is independent of RAS-GAP activity. It has been shown that mutations of K417 and K567 in the GAP catalytic domain lead to the loss of catalytic activity of RASAL2 toward RAS/ERK signaling (28). To
We found that while the expression of the mouse miR-203, which bears a sequence that is 100% identical to that of human miR-203, was decreased in 4T1-LM cells compared with the parental 4T1 cells, the expression of RASAL2 was increased (Figure 4B), accompanied by an increased invasiveness of 4T1-LM cells (Supplemental Figure 6A). Since the mouse and the human RASAL2 protein sequences are over 96% identical, we next ectopically overexpressed human RASAL2 in parental 4T1 cells and asked whether the ectopic RASAL2 is sufficient to increase invasion in vitro and metastasis in vivo. Indeed, ectopic overexpression of RASAL2 in 4T1 cells increased the invasiveness (Supplemental Figure 6B). Measurement of spontaneous lung metastasis through orthotopic transplant of 4T1 and 4T1 RASAL2 cells into mammary gland fat pads of test whether RAS-GAP activity is required for RASAL2 function in TNBC, we made a GAP activity–deficient mutant of RASAL2, together with a GAP domain deletion mutant, and performed the rescue experiment in RASAL2 knockdown cells. The results showed that the GAP activity–deficient mutant retained its activity to restore invasion upon RASAL2 knockdown in TNBC cells, indicating that GAP catalytic activity is dispensable for oncogenic RASAL2 function. In contrast, the GAP deletion mutant failed to do so, indicating that RASAL2 still required the presence of the GAP domain to exert its oncogenic function (Figure 3G).

To study RASAL2 function in vivo, we first made use of the basal-like 4T1 mouse mammary tumor cells and compared the expression levels of RASAL2 and miR-203 in parental 4T1 cells and a metastatic subline derived from the lung metastasis (referred to as 4T1-LM) following mammary gland fat pad injection (Figure 4A). We found that while the expression of the mouse miR-203, which bears a sequence that is 100% identical to that of human miR-203, was decreased in 4T1-LM cells compared with the parental 4T1 cells, the expression of RASAL2 was increased (Figure 4B), accompanied by an increased invasiveness of 4T1-LM cells (Supplemental Figure 6A). Since the mouse and the human RASAL2 protein sequences are over 96% identical, we next ectopically overexpressed human RASAL2 in parental 4T1 cells and asked whether the ectopic RASAL2 is sufficient to increase invasion in vitro and metastasis in vivo. Indeed, ectopic overexpression of RASAL2 in 4T1 cells increased the invasiveness (Supplemental Figure 6B). Measurement of spontaneous lung metastasis through orthotopic transplant of 4T1 and 4T1 RASAL2 cells into mammary gland fat pads of
NOD/SCID mice by bioluminescence imaging as well as lung tissue staining revealed that although the RASAL2 overexpression had little effect on the primary tumor growth (Figure 4C), it significantly increased the burden of lung metastasis (Figure 4D).

We further used MB231-LN cells that express a luciferase reporter to investigate the role of RASAL2 in TNBC metastasis. RASAL2 knockdown in MB231-LN cells expressing a short hairpin RNA targeting RASAL2 or the nontargeting control cells implanted in mouse mammary gland fat again produced no appreciable effect on primary tumor growth (Figure 4E) but significantly decreased the burden of lung metastasis (Figure 4F), which consequently resulted in prolonged survival of the tumor-bearing mice ($p = 0.008$) (Figure 4G).

Next, we evaluated the development of lung metastasis following the injection of MB231-LN cells via the mouse tail vein. In this model, RASAL2 knockdown also significantly inhibited lung metastasis (Figure 4H) and prolonged the survival of tumor-bearing mice (Figure 4I). Although the effect was not as marked as that seen in orthotopic models, this showed that RASAL2 is also important in allowing circulating tumor cells to establish metastatic colonies, a later step of metastasis. Taken together, both of gain-of-function and loss-of-function in vivo studies demonstrate a crucial role for RASAL2 in driving TNBC metastasis.

RASAL2 acts to activate the small GTPase RAC1 for mesenchymal cell invasion. Previous studies have shown that some GAPs for one family of small GTPases can act to promote the activity of other families of small GTPases. For example, the RAS-GAP protein p120 RAS-GAP, also called RAC1, can activate the RHOA GTPase through interaction with and inhibition of the RHOA-GAP protein DLC1 tumor suppressor (32). To determine whether this was the case with RASAL2, we examined whether RASAL2 was able to regulate the activities of the other small GTPases family members, including RAC1, RHOA, and CDC42, all known to promote cancer invasion and metastasis (33–36). Here, we found that, by affinity pull-down analysis of respective GTP-bound GTPases, RASAL2 overexpression in 4T1 cells resulted in increased RAC1 activity (GTP-bound RAC1), decreased RHOA activity, and no change in CDC42 activity (Figure 5A). Conversely, RASAL2 knockdown in MB231-LN and BT-549 cells led to reduction of RAC1 activity and increased RHOA activity (Figure 5B). In both above experiments, RASAL2 manipulations did not change RAS-GTP levels or downstream ERK phosphorylation (Supplemental Figure 6C and D). In contrast, ectopic expression of RASAL2 in 2 luminal B breast cancer cell lines, BT474 and MB361, resulted in downregulation of RAS-GTP and ERK phosphorylation as well as decreased cell invasion and soft agar growth (Supplemental Figure 7A–C). Moreover, both wild-type RASAL2 and GAP activity–deficient mutant RASAL2, but not GAP domain deletion mutant RASAL2, activated the RAC1 activity in TNBC (Figure 5C). By contrast, the tumor suppressor activity of RASAL2 in luminal BT474 and MB361 cells indeed requires RASAL2’s GAP activity (Supplemental Figure 7D). These findings demonstrate a context-dependent role of RASAL2 in breast cancer.

RAC1 and RHOA are known to be mutually antagonistic, though both can promote cell invasion and motility through different mechanisms (37–39). While RAC1 drives mesenchymal motility, in which the cells are elongated, RHOA drives amoeboid motility, in which the cells are round (40–43). Consistent with this notion, we observed that, when RASAL2 was knocked down and cultured in 3D Matrigel, MB231-LN cells underwent a change from an elongated morphology to a rounded form (Figure 5D). In addition, expression levels of several MMP family members, which are hallmark indicators of RAC1-driven mesenchymal motility (38, 44, 45), were markedly decreased upon RASAL2 knockdown in TNBC cells (Figure 5E).

Critically, like RASAL2, ectopic RAC1 increased invasion and MMP expression and robustly rescued the RASAL2 knockdown effects (Figure 5, F and G), confirming a functional link between RASAL2 and RAC1. Collectively, these results provide evidence that RASAL2 promotes mesenchymal cell invasion in TNBC through activating RAC1 activity at large.

RASAL2 regulates RAC1 activity through binding to and antagonizing RAC1 GAP protein, ARHGAP24. Next, we investigated the molecular mechanism by which RASAL2 regulates RAC1 activity. RASAL2 did not coimmunoprecipitate with RAC1 (Figure 6A and data not shown), suggesting that RASAL2 may regulate RAC1 activity indirectly. As activity of small GTPases is often negatively regulated by its GAP proteins, we explored the possibility that RASAL2 may promote RAC1 activity by antagonizing a RAC1 GAP protein. Two RAC1 GAPs, ARHGAP24 (also known as FilGAP) and ARHGAP22, have been previously shown to be involved in breast cancer cell invasion and motility (46–48) and thus were investigated for their potential roles in mediating RASAL2 activity toward RAC1. To do this, we first determined whether RASAL2 can be found in the same protein complex with ARHGAP24 or ARHGAP22. In both MB231-LN and BT-549 cells, we found that the endogenous RASAL2 coimmunoprecipitated with endogenous ARHGAP24 but not ARHGAP22 in TNBC cells (Figure 6A and data not shown), and this interaction was not detected in luminal cells (Supplemental Figure 7E). Furthermore, both wild-type RASAL2 and GAP activity–deficient mutant RASAL2 interacted with ARHGAP24, while GAP deletion mutant RASAL2 did not (Figure 6B). This result shows that RASAL2 requires the GAP domain but not the GAP activity to interact with ARHGAP24.

We next investigated whether RASAL2 interaction with ARHGAP24 affects its activity. It has been shown that serine phosphorylation of ARHGAP24 promotes its activity to regulate RAC1 (47). We found that, in cells transfected with ARHGAP24, RASAL2, or both, immunoprecipitated ARHGAP24 showed reduced serine phosphorylation in RASAL2 and ARHGAP24 cotransfected cells compared with cells transfected with ARHGAP24 alone (Figure 6C). This finding supports that RASAL2 interaction with ARHGAP24 negatively regulates ARHGAP24 activity.

Finally, we investigated the functional interplay between RASAL2 and ARHGAP24 in regulating RAC1 activity and cell invasiveness. Consistent with RAC1 GAP proteins, ARHGAP24 knockdown in TNBC cells resulted in enhanced activity of RAC1 and invasion capacity (Figure 6D) and thus restored the RAC1 activity and cell invasion suppressed upon RASAL2 knockdown (Figure 6E). Conversely, ectopic overexpression of ARHGAP24 in TNBC cells resulted in suppression of cell invasion and RAC1 activity, which were rescued at least partially by coexpression of RASAL2 (Figure 6F). Collectively, these results support that RASAL2 enhances RAC1 activity toward TNBC cell invasion, at least in part, through binding to and antagonizing the RAC1 GAP protein ARHGAP24.
miR-203–targeted RASAL2/RAC1 regulates mesenchymal invasion, without affecting EMT. miR-203 treatment in TNBC cells also resulted in suppression of RAC1-GTP (Figure 7B) as well as MMPs (Figure 7C). Similarly, like RASAL2, ectopic RAC1 was also able to rescue the anti-invasive effect of miR-203 (Figure 7D). These findings confirmed a role of RASAL2/RAC1 as a functional target of miR-203 in TNBC cell invasion.

We next assessed whether miR-203 is able to affect the EMT of TNBC cells. To address this, rescue experiments using ectopic RASAL2/RAC1 in miR-203–treated cells were performed. In both MB231-LN and BT-549 cells, ectopic RASAL2 expression was able to rescue the anti-invasive effect of miR-203 (Figure 7A).
Thus, compared with miR-200a/b, miR-203 does not seem to be a strong EMT regulator in TNBC. Taken together, these results support the conclusion that the anti-invasive effect of miR-203 in TNBC was mediated through targeting RASAL2/RAC1 activity, rather than targeting EMT.

**Figure 8.** The context-dependent role of RASAL2 in breast cancer is dependent on EMT status. (A) Invasion assay in BPLE, BPLER, HMLE, and HMLER cells with stable ectopic RASAL2 expression and Western blot analysis of protein levels. (B) Soft agar growth of indicated cell lines. (C) Western blot showing the levels of the active form of indicated small GTPases (GTP-bound RAC1 and RAS) and the total levels of controls upon ectopic RASAL2 expression in BPLER and HMLER cells. (D) Invasion assay and Western blot showing the levels of the active form of RAC1 and the total levels of controls in BPLER cells expressing ectopic RASAL2 with or without CDH1 knockdown and soft agar assay of the same cell lines. (E) BT474 cell morphology change upon CDH1 knockdown. Original magnification, ×100. (F) Invasion assay and Western blot showing indicated proteins in BT474 cells expressing ectopic RASAL2 with or without CDH1 knockdown. (G) A schematic model showing context-dependent roles of RASAL2 in breast cancer. The data shown represent mean ± SEM of 3 independent or replicate experiments. *P < 0.05, **P < 0.01, ***P < 0.001.

**Context-dependent roles of RASAL2 in breast cancer are dependent on EMT status.** Because RASAL2 is tumor suppressive in luminal breast cancer but oncogenic in TNBC, we next sought to determine whether EMT status plays a role in this context-dependent phenomenon suggestive of EMT reversal (Figure 7E), which was further confirmed by confocal imaging analysis of the epithelial marker E-cadherin (CDH1) and the mesenchymal marker vimentin (VIM) (Figure 7F). Further assessment of a panel of EMT-related genes by qPCR showed that, in both MB231-LN and BT-549 cells, miR-200a/b treatment induced the expression of CDH1 and decreased the expression of VIM, ZEB1/2, and SNAI1/2, while miR-203 treatment did not induce such molecular changes, though it modestly decreased SNAI2 (also known as SLUG) expression (Figure 7G).
functional switch. This hypothesis first arose from our observation that, in nonmesenchymal (epithelial) TNBC cell lines, such as HCC1806 and HCC1937, in which RASAL2 was equally expressed at levels as high as those in mesenchymal TNBC cells, RASAL2 knockdown failed to inhibit the cell invasion (Supplemental Figure 8A). As previously reported and also shown here, miR-200a/b was expressed abundantly in luminal or nonmesenchymal TNBC cells but not in mesenchymal TNBC cells (Supplemental Figure 8B) (24). We asked whether miR-200a/b inhibition in the nonmesenchymal TNBC cells would facilitate EMT induction and thus stimulate RASAL2 activity in these cells. Indeed, antagonir inhibition of miR-200a/b markedly induced mesenchymal markers in HCC1806 and HCC1937 cells (Supplemental Figure 8C) and increased cell invasion, which was then abolished by RASAL2 knockdown (Supplemental Figure 8D). This initial finding raised the possibility that an EMT status is probably a prerequisite for RASAL2 to function as an oncogene.

To directly address this issue, we took the advantage of a series of immortalized (BPLE and HMLE) and respectively transformed (BPLER and HMLER) human mammalian cell lines that express differential luminal or basal markers. BPLE and BPLER cells expressed more luminal epithelial gene markers and expressed high levels of E-cadherin but low levels of vimentin, while HMLE and HMLER cells expressed more basal epithelial gene markers and showed expression levels opposite of those of BPLE and BPLER cells for E-cadherin and vimentin (refs. 50, 51, and Figure 8A). Consistent with the context-dependent role of RASAL2, as we predicted, ectopic expression of RASAL2 in more luminal-like BPLE and BPLER cells reduced cell invasion (Figure 8A) and soft agar growth (Figure 8B), while it enhanced cell invasion of HMLER cells, though it did not change much of its soft agar growth (Figure 8, A and B). Consistently, we saw reduced RAS-GTP and ERK phosphorylation upon ectopic RASAL2 expression in BPLER cells but increased RAC1-GTP in HMLER cells (Figure 8C). Intriguingly, E-cadherin knockdown in BPLER cells abolished the inhibitory effects of ectopic RASAL2 on invasion, growth, RAS-GTP, and ERK phosphorylation and stimulated ectopic RASAL2 to activate RAC-GTP (Figure 8D). Moreover, in luminal B breast cancer BT474 cells, E-cadherin knockdown induced an EMT morphology (Figure 8E), and again, under this condition, ectopic RASAL2 lost its ability to suppress Ras activity and cell invasion in BT474 cells; rather, it increased the cell invasion and RAC1 activity (Figure 8F). Collectively, these findings demonstrate that induction of mesenchymal status is inhibitory for the tumor-suppressive RAS-GAP activity but required for the oncogenic activity of RASAL2 to promote RAC1 activity and invasion capacity. These findings have thus provided a mechanistic insight into the context-dependent role of RASAL2 in breast cancer, as shown in a proposed model (Figure 8G).

Discussion
Dissecting the molecular pathways that drive breast cancer invasion and metastasis remains crucial to understanding the disease progression and development of therapeutic strategies. Here, we provide evidence for an anti-invasive miR-203–targeted RASAL2/RAC1 pathway in TNBC invasion and metastasis. In contrast to a previously described role as a tumor suppressor in luminal breast tumors via targeting RAS activity (28), RASAL2 is overexpressed in TNBC, in which it predicts poor disease outcomes and directs mesenchymal invasion and metastasis through promoting small GTPase RAC1 activity. Our study demonstrates the context dependency of RASAL2 in breast cancer and provides mechanistic insights into the oncogenic activity of RASAL2 in TNBC.

Our findings in TNBC appear to be in contrast with that of a previous finding in luminal B breast cancer, in which RASAL2 was found to act as a RAS-GAP tumor suppressor whose downregulation due to promoter hypermethylation resulted in inactivation of RAS signaling and increased growth and metastasis (28). As opposed to the downregulation of RASAL2 in the luminal B subtype, we found that RASAL2 was overexpressed in 30% to 40% of TNBC and ER-negative tumors, and this downregulation could be due to a loss of miR-203 expression, as we identified here, and could also be in part due to possible gene amplification, as revealed by TCGA genomic analysis. In a meta-analysis of breast cancer, including multiple cohorts, we found that RASAL2 expression was positively associated with poorer disease outcomes in TNBC and ER-negative tumors but had an opposite trend in luminal tumors. In addition, higher RASAL2 expression was found to be associated with increased incidence of metastasis and recurrence in TNBC or ER-negative tumors, further supporting its role in disease progression and possibly also chemoresistance. Importantly, RASAL2 upregulation and gene copy number gain were also found in high-grade serous ovarian cancer, which has been recently found to share a similar molecular portrait to TNBC through large-scale genomic analyses (30), and were also associated with metastatic progression and poor outcomes in multiple ovarian cancer cohorts. This suggests that the oncogenic role of RASAL2 is not limited to TNBC. The contradictory roles of RASAL2 in TNBC and luminal cancers underscore an important context dependency of RASAL2 function in human cancers.

Experimentally, both gain-of-function and loss-of-function analyses in vitro and in vivo have demonstrated the oncogenic role of RASAL2 in TNBC invasion and metastasis. Mechanistically, we show that the oncogenic function of RASAL2 in TNBC is irrelevant to RAS status, as RASAL2 depletion attenuates the invasive phenotype in both RAS wild-type and mutated TNBC cells and does not affect RAS activity or the downstream MAPK signaling in TNBC. Rather, RASAL2 deletion effectively abolished the activity of RAC1, which is known to be involved in mesenchymal cell invasion (38, 44, 52, 53). We further demonstrate that the ability of RASAL2 to regulate RAC1 is through binding to and antagonizing RAC1 GTPase-activating protein ARHGPAP24, which, in the absence of RASAL2, functions to inhibit RAC1 activity.

We show that the context dependency of RASAL2 in breast cancer depends on the EMT status. This is demonstrated by using well-defined human mammalian epithelial cell line models that express different mesenchymal and epithelial markers. RASAL2 acts as an oncogene to promote invasion and RAC1 activity in basal HMLER cells with reduced E-cadherin but functions as a tumor suppressor to reduce growth and RAS activity in more luminal BPLER cells that express abundant E-cadherin. E-cadherin knockdown in BPLER cells abolished the tumor suppressor activity of RASAL2 and stimulated it to induce RAC1 activity. The same was also seen in luminal breast cancer cell line BT474, in which inducing EMT by E-cadherin knockdown inactivates the RASAL2
tumor suppressor activity. Thus, the molecular traits of EMT, such as E-cadherin, seem to be crucial for RASAL2 to be oncogenic but inhibitory for its tumor suppressor activity. Given the functional complexity and heterogeneity of molecular cancer pathways, it perhaps not so surprising that such paradoxes are often found in human cancers. This phenomenon seems to resemble TGF-β signaling, which acts as an oncogene in basal breast tumors, in which it promotes EMT and metastasis, and acts as a tumor suppressor in luminal tumors, in which it is downregulated (54, 55).

Although miR-203 has been previously shown to inhibit EMT by targeting ZEB2 in lung and prostate cancers, miR-203 does not appear to directly regulate EMT in TNBC because, unlike miR-200, miR-203 did not reverse EMT-associated morphological and molecular changes in TNBC cells. Thus, miR-203 acts to repress TNBC invasion independently of EMT modulation, as seen in other cancers. Although loss of miR-203 does not seem to induce the EMT process itself, it potentiates mesenchymal invasion in TNBC cells through modulating RASAL2/RAC1 activity. This is consistent with the previous finding that RAC1 activation mediates motility of cancer cells undergoing EMT (56). Thus, we propose a model in which the combined loss of miR-200s and miR-203 in TNBC work collaboratively to facilitate invasion and metastasis in TNBC.

Although EMT appears to be rare within primary TNBC tumors, it is highly enriched (up to 100%) in circulating breast tumor cells of patients with TNBC (57). Given the strong association of circulating tumor cells with breast cancer metastatic progression (57), the discovery of miR-203-targeted RASAL2/RAC1 as a crucial regulator of mesenchymal invasion provides a rational for therapeutic targeting of RASAL2 for TNBC metastasis. This can be developed potentially into a highly needed therapeutic target in TNBC, for which poor clinical outcome is compounded by the absence of any targeted therapeutics. Further studies to evaluate the potential of RASAL2 as both a predictive and prognostic marker in TNBC will provide more accurate stratification and also a means of reducing disease recurrence in the 30% to 40% of patients with TNBC who develop early relapse despite chemotherapy.

Methods
Please refer to the Supplemental Methods section for more detailed information.

Cell lines and reagents. The breast cancer cell lines used in this study were purchased from ATCC. BPLE and BPLER cells were gifts from Robert Weinberg (Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA) and were maintained in WIT-T Culture Medium (Stemgent). MB231-LN (MDA-MB-231-Luc-D3H2LN) cells were purchased from Perkin Elmer. Constructs of ectopic RASAL2 expression, siRNAs, and shRNAs for RASAL2 knockdown can be found in the Supplemental Methods. For primers and siRNA sequences, see Supplemental Table 2.

miRNA profiling and quantitative RT-PCR validation. Total RNAs were isolated and purified with the Qiagen miRNeasy Mini Kit (catalog no. 217004). The miRNA expression array hybridization was performed using Agilent Human miRNA Microarray Kit V3 (Agilent, catalog no. G4470C), and data analysis was performed as previously described (24). Detailed information and additional assays for validation of RT-PCR transcription can be found in Supplemental Methods.

IHC. Breast cancer TMA slides (BR1505 and BRM961) were purchased from USA Biomax. RASAL2 expression was probed with RASAL2 antibody (Novus Biologicals, catalog no. NB1-82579). Additional details of IHC are provided in the Supplemental Methods.

Statistics. All in vitro experiments were repeated at least 3 times, unless stated otherwise, and data are reported as mean ± SEM. To normalize the expression of each patient cohort, expression values were normalized by calculating the z-score for each independent data set. The differences were assessed using 2-tailed Student’s t test or 1-way ANOVA for multiple group comparisons using GraphPad Prism 6 software. Animal study survival curves were plotted using Kaplan-Meier analysis, and the statistical parameters were calculated by log-rank (Mantel-Cox) test using Graphpad Prism. In all statistical tests, 𝑃 ≤ 0.05 was considered significant unless stated otherwise.

Study approval. Human tissue samples were provided by John Wayne Cancer Institute and Tan Tock Seng Hospital, and studies with these samples were approved by institutional review boards of each institution, respectively. Informed written consent was obtained from each individual who agreed to provide tissue for research purposes. All animal studies were conducted in compliance with animal protocols approved by the A*STAR-Biopolis Institutional Animal Care and Use Committee of Singapore.

Acknowledgments
We thank the histopathology department of the Institute of Molecular and Cell Biology, A*STAR, for their service in IHC staining and analysis. We thank Mei Yee Aau for microarray hybridization and Chew Hooi Wong for assistance with tumorschere assay. We thank Robert Weinberg’s lab (Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA) for providing BPLE/BPLER and HMLE/HMLER cell lines and Wai Leong Tam for technical guidance. This work was supported by A*STAR of Singapore, The National Healthcare Group clinician-scientist career scheme (CSCS/12004 to E.Y. Tan), the Margie and Robert E. Petersen Foundation, the ABC Foundation, and the Leslie and Susan Gonda (Goldschmied) Foundation (to D.S.B. Hoon, D.M. Marzese, and J. Wang).

Address correspondence to: Qiang Yu, Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, 60 Biopolis Street, 02-01, Singapore 138672. Phone: 65.6478.8127; E-mail: yqyu@gis.a-star.edu.sg.


